Kerendia®
Drug - Kerendia® (finerenone) [Bayer Healthcare Pharmaceuticals, Inc.]
April 2022
Therapeutic area - Diuretics
Initial approval criteria
- Patient is 18 years of age or older AND
- Prescribed by or in consultation with an endocrinologist, cardiologist, or nephrologist AND
- Patient has the diagnosis of chronic kidney disease and type 2 diabetes AND
- Patient is currently taking a maximally tolerated angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), unless contraindicated AND
- Chart notes have been submitted with baseline labs showing all of the following:
- Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m2 and < 75 mL/min/1.73 m2 AND
- Urine albumin-to-creatinine ratio ≥ 30 mg/g AND
- Serum potassium level ≤ 5.0 mEq/L AND
- Patient is not taking strong CYP3A4 inhibitors concomitantly AND
- Patient does not have adrenal insufficiency AND
- Patient does not have severe hepatic impairment (Child-Pugh Class C)
- Initial approval is for 3 months
Renewal criteria
- Patient continues to meet initial approval criteria AND
- Patient has documented disease improvement and/or stabilization AND
- Patient has documented periodic serum potassium monitoring
- Renewal approval is for 6 months
Quantity limits
- Tablets, 10 mg and 20 mg: 34 tablets per 34 days
Questions?
MHCP Provider Resource Center 651-431-2700 or 800-366-5411
